Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Kura Oncology, Inc. (KURA)
|
Add to portfolio |
|
|
|
| Price: |
$27.52
| | Metrics |
| OS: |
74.2
|
M
| |
-31
|
% ROE
|
| Market cap: |
$2.04
|
B
| |
-30
|
% ROIC
|
|
Net cash:
|
$477
|
M
| |
$6.43
|
per share
|
|
EV:
|
$1.57
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($125)
|
M
| |
|
|
| EPS |
($2.05)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 96.8 | 0.0 | 85.5 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | 13.2% | | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 96.8 | 0.0 | 85.5 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | 100.0% | | 100.0% | | | | |
| Selling, general and administrative | 139.9 | | 131.3 | | 91.9 | 67.5 | | |
| Research and development | | | | | | | 46.8 | 26.4 |
| General and administrative | | 47.1 | | 46.5 | | | 16.1 | 9.7 |
| EBIT | -148.4 | 49.8 | -133.7 | 39.0 | -97.6 | -77.3 | -65.6 | -35.9 |
| EBIT margin | | 51.4% | | 45.6% | | | | |
| Pre-tax income | -135.8 | -135.8 | -130.5 | -130.5 | -89.6 | -63.1 | -60.4 | -35.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -135.8 | -135.8 | -130.5 | -130.5 | -89.6 | -63.1 | -60.4 | -35.4 |
| Net margin | | -140.3% | | -152.6% | | | | |
| |
| Diluted EPS | ($2.03) | ($2.03) | ($1.97) | ($1.97) | ($1.69) | ($1.51) | ($1.72) | ($1.52) |
| Shares outstanding (diluted) | 67.0 | 67.0 | 66.4 | 66.4 | 53.1 | 41.9 | 35.2 | 23.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|